Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer

Kenzo Sonoda, Hideaki Yahata, Akimasa Ichinoe, Okugawa Kaoru, Kaneki Eisuke, Yoshiaki Kawano, Hironori Kenjo, Tatsuhiro Ogami, hiroshi yagi, Ohga Saiji, Kaori Asai, Katsumasa Nakamura, Hiroshi Honda, Kiyoko Kato

研究成果: ジャーナルへの寄稿評論記事

2 引用 (Scopus)

抄録

Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.

元の言語英語
ページ(範囲)3447-3454
ページ数8
ジャーナルAnticancer research
35
発行部数6
出版物ステータス出版済み - 6 1 2015

Fingerprint

Fluorouracil
Uterine Cervical Neoplasms
Cisplatin
Drug Therapy
Disease-Free Survival
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer. / Sonoda, Kenzo; Yahata, Hideaki; Ichinoe, Akimasa; Kaoru, Okugawa; Eisuke, Kaneki; Kawano, Yoshiaki; Kenjo, Hironori; Ogami, Tatsuhiro; yagi, hiroshi; Saiji, Ohga; Asai, Kaori; Nakamura, Katsumasa; Honda, Hiroshi; Kato, Kiyoko.

:: Anticancer research, 巻 35, 番号 6, 01.06.2015, p. 3447-3454.

研究成果: ジャーナルへの寄稿評論記事

Sonoda, Kenzo ; Yahata, Hideaki ; Ichinoe, Akimasa ; Kaoru, Okugawa ; Eisuke, Kaneki ; Kawano, Yoshiaki ; Kenjo, Hironori ; Ogami, Tatsuhiro ; yagi, hiroshi ; Saiji, Ohga ; Asai, Kaori ; Nakamura, Katsumasa ; Honda, Hiroshi ; Kato, Kiyoko. / Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer. :: Anticancer research. 2015 ; 巻 35, 番号 6. pp. 3447-3454.
@article{3895bb9c9ea6495e8b0199a86d967256,
title = "Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer",
abstract = "Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.",
author = "Kenzo Sonoda and Hideaki Yahata and Akimasa Ichinoe and Okugawa Kaoru and Kaneki Eisuke and Yoshiaki Kawano and Hironori Kenjo and Tatsuhiro Ogami and hiroshi yagi and Ohga Saiji and Kaori Asai and Katsumasa Nakamura and Hiroshi Honda and Kiyoko Kato",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "35",
pages = "3447--3454",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer

AU - Sonoda, Kenzo

AU - Yahata, Hideaki

AU - Ichinoe, Akimasa

AU - Kaoru, Okugawa

AU - Eisuke, Kaneki

AU - Kawano, Yoshiaki

AU - Kenjo, Hironori

AU - Ogami, Tatsuhiro

AU - yagi, hiroshi

AU - Saiji, Ohga

AU - Asai, Kaori

AU - Nakamura, Katsumasa

AU - Honda, Hiroshi

AU - Kato, Kiyoko

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.

AB - Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.

UR - http://www.scopus.com/inward/record.url?scp=84931448208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931448208&partnerID=8YFLogxK

M3 - Review article

C2 - 26026109

AN - SCOPUS:84931448208

VL - 35

SP - 3447

EP - 3454

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -